[EN] QUINAZOLINONE-DERIVATIVES AND THEIR USE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING PARP ENZYME INHIBITORY EFFECT [FR] DERIVES DE QUINAZOLINONE ET UTILISATION DE CEUX-CI DANS LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES POSSEDANT DES EFFETS INHIBITEURS D'ENZYME
QUINAZOLINONE-DERIVATIVES AND THEIR USE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING PARP ENZYME INHIBITORY EFFECT
申请人:Pécsi Tudomànyegyetem
公开号:EP1622881B1
公开(公告)日:2010-05-26
[EN] QUINAZOLINONE-DERIVATIVES AND THEIR USE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING PARP ENZYME INHIBITORY EFFECT<br/>[FR] DERIVES DE QUINAZOLINONE ET UTILISATION DE CEUX-CI DANS LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES POSSEDANT DES EFFETS INHIBITEURS D'ENZYME
申请人:SUEMEGI BALAZS
公开号:WO2004096779A1
公开(公告)日:2004-11-11
The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general formula (I) R1 stands for either hydrogen or a group of general formula (a); R2 stands for a) hydrogen or C1-6 alkyl group, if R1 is other than hydrogen, and b) if R1 is hydrogen, then R2 may be a group of general formula (b), (c) or (d). The subject of the present invention also embraces the preparation processes of the compounds described above.